Tag results:

clinical trial

PepGen Announces First Participant Dosed in a Phase I Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

[PepGen, Inc.] PepGen, Inc. announced a critical clinical milestone for PGN-EDO51, the company’s lead product candidate for the treatment of Duchenne muscular dystrophy patients whose mutations are amenable to an exon 51 skipping approach.

PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

[Adrenomed AG] Adrenomed AG announced that its proprietary sepsis drug candidate Adrecizumab received a funding commitment of € 7.4 million from the German Federal Ministry of Education and Research as part of the German funding initiatives for the clinical development of COVID-19 drugs and their manufacturing capabilities.

Development of iPSC-Based Clinical Trial Selection Platform for Patients with Ultrarare Diseases

[Science Advances] Scientists reported an 18-year-old patient with ultrarare Leigh-like syndrome. They established an iPSC–based platform for this patient, and assessed the efficacy of a panel of drugs.

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase IIA Trial for the Treatment of Gastroparesis

[Processa Pharmaceuticals, Inc.] Processa Pharmaceuticals, Inc., announced that it has enrolled its first patient in the Phase IIA clinical trial of PCS12852 in patients with moderate to severe gastroparesis.

NGM Bio Announces Initiation of Phase I/Ib Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

[NGM Biopharmaceuticals, Inc.] NGM Biopharmaceuticals, Inc. announced it has dosed the first patient in a Phase I/Ib clinical trial of NGM831 for the treatment of patients with advanced solid tumors.The trial expects to enroll adult patients with multiple tumor types, including pancreatic cancer, breast cancer and prostate cancer.

BriaCell Advances Preparatory Work for New Bria-OTSâ„¢ Breast Cancer Clinical Trial

[BriaCell Therapeutics Corp.] BriaCell Therapeutics Corp., announced that its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTSâ„¢, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.

Popular